Abstract
Ghrelin is a gut–brain hormone, which stimulates food intake and controls energy balance. Recently, it has been shown that ghrelin may also play a role in the regulation of blood pressure (BP) by acting at the sympathetic nervous system. In the present study we genotyped six variants of the ghrelin gene and its promoter, and tested whether these single nucleotide polymorphisms (SNPs) were associated with BP levels in participants of the Finnish Diabetes Prevention Study.
The Finnish Diabetes Prevention Study was a longitudinal study where 522 subjects with impaired glucose tolerance were randomized into either an intervention or control group. DNA was available from 507 subjects (mean body mass index [BMI] 31.2 ± 4.5 kg/m
2, age 55 ± 7 years). All six SNPs were screened by the restriction fragment length polymorphism method.
Subjects with the most common genotype combination of the following four SNPs, -604G/A, -501A/C, Leu72Met, and Gln90Leu, had the lowest systolic (131 ± 11
v 137 ± 13 mm Hg,
P = .003) and diastolic BP levels (79 ± 7
v 83 ± 7 mm Hg,
P = .004) at the baseline of the study and during 3 years of follow-up compared to all other genotypes. Adjustments for age, gender, antihypertensive medication, BMI, waist circumference, and alcohol intake did not change this association.
Several ghrelin gene variations were associated with BP levels in subjects with impaired glucose tolerance.